On Thursday, Shares of Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR), gained 3.83% to $9.49.
Brazil’s state-run oil company Petroleo Brasileiro SA could be forced to re-publish first-quarter results after it comprised of a contract accomplished after the reporting period, the president of Brazil’s markets regulator said on Wednesday, according to Reuters.
Petrobras, as the company is known, comprised of 1.3 billion reais ($433 million) on its balance sheet related to a contract with state-run utilities company Eletrobras that was only closed on May 7, 37 days after the end of the first quarter.
Leonardo Pereira, president of markets regulator CVM, said a decision would be made based on guidance from the Accounting Pronouncements Committee (CPC), an independent body which lays out norms for reporting practices that are usually adopted by the CVM. Reuters Reports.
Petróleo Brasileiro S.A. Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets.
Shares of American International Group, Inc. (NYSE:AIG), inclined 0.43% to $60.22, during its last trading session, hitting its highest level.
American International Group, declared that Peter D. Hancock, President and Chief Executive Officer, will present at the Deutsche Bank Global Financial Services Investor Conference on Wednesday, June 3, 2015, at 11:00 a.m. EDT in New York City.
American International Group, Inc. provides insurance products and services for commercial, institutional, and individual customers in the United States, the Asia Pacific, and internationally.
At the end of Thursday’s trade, Shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), gained 4.17% to $0.75.
Rexahn Pharmaceuticals, declared it will present three posters at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting taking place at the McCormick Place Convention Center in Chicago, Illinois on May 29-June 2, 2015. An additional abstract will be accessible on-line.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer and other medical needs. The company has three clinical stage oncology candidates: Archexin, RX-3117, and Supinoxin (RX-5902), in addition to a pipeline of preclinical compounds to treat multiple types of cancer.
Finally, Aéropostale, Inc. (NYSE:ARO), ended its last trade with 2.78% gain, and closed at $2.59.
Aéropostale, stated results for the first quarter of fiscal 2015, and offered guidance for the second quarter of fiscal 2015.
First Quarter Performance
For the first quarter of fiscal 2015, net sales reduced 20% to $318.6 million, from $395.9 million in the year ago period. Comparable sales, counting the e-commerce channel, for the first quarter reduced 11%, contrast to a decrease of 13% for the corresponding 13-week period ended May 3, 2014.
The Company stated a net loss for the first quarter of fiscal 2015 of $45.3 million, or $0.57 per diluted share, which comprised of:
- an after-tax charge of $2.3 million, or $0.03 per diluted share, resulting from store closing costs, partially offset by
- an after-tax benefit of $1.1 million, or $0.02 per diluted share, resulting from a retirement plan settlement adjustment.
Aéropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
